Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Massachusetts drug‑checking network shows Xylazine emergence in 2020–2022 then decline; metetomidine rising — MADS urges expanded, funded testing hubs
Summary
State drug‑checking researchers told the commission that Xylazine was first detected in Massachusetts in 2020, appeared in toxicology data in 2022, and that 2025 MADS surveillance shows a decline in Xylazine with an increase in metetomidine detections.
Researchers from the Massachusetts Drug Supply Data Stream (MADS) described how community drug‑checking and laboratory confirmatory testing provide near‑real‑time intelligence on an evolving unregulated drug supply and inform public‑health action.
Tracy Green, principal investigator for MADS, summarized the tools used by community partners: technician‑run Fourier transform infrared (FTIR) spectrometers for on‑site scans, immunoassay test strips (including Xylazine and fentanyl strips) and confirmatory laboratory testing (GC‑MS/LC‑QTOF). Green told the commission that MADS began…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
